Skyline Corporate Communications Group, LLC’s Post

This #NationalDiabetesWeek2024 we unite to raise #awareness and champion advancements in #diabetes care. From innovative treatments to groundbreaking research, Pacific Clinical Research Group™ is privileged to work with #medicaldevice pioneers like Endogenex and world class #physicians across #Australia and #NewZealand who are passionate and committed to better management and treatment for #diabetes as well as advocating for the easier access that patients deserve. We are so very proud to support the incredible work being done by the Diabetes Technology Research Group, Catriona Sims Elif Ekinci David O'Neal & Lian Cunningham. People living with diabetes should be able to access the life-saving technology they need to live well. This year we are shining a light on the impact of #diabetestech and what needs to be done to improve access and together we can create a healthier future for everyone Diabetes AustraliaThe Australian Centre for Accelerating Diabetes Innovations (ACADI) #DiabetesWeek #Australia #Healthcare #NationalDiabetesWeek2024 #cro #clinicaltrials

#HealthWatch #GoLab A recent comprehensive study, by the University of Hong Kong (#HKU), conducted in an outpatient clinic in Hong Kong highlights the exceptional performance of SARS-CoV-2 &Influenza A/B &RSV Antigen Kit (Colloidal Gold) manufactured by Goldsite Diagnostics Inc. The study underscores the practical benefits of #Goldsite 4 in One Combo Rapid Test. The tests were conducted in real-world settings, involving a diverse patient population. The findings reflect the 4 in One Combo Test Kit's robust performance across different age groups and varying viral loads, reinforcing their reliability in everyday #clinical practice. Read more🔗 https://lnkd.in/e3K_wybW #respiratory #influenza #rapidtests #AntigenTest

In #Indonesia, over 18 million people are living with #diabetes, and nearly 30% of them face eye conditions that significantly increase their risk of vision loss. Roche is partnering with ophthalmologists, retinal specialists, ophthalmic surgeons, and leading medical associations to build an effective national diabetic retinopathy (DR) screening program. Early #screening for diabetic retinopathy is crucial to reducing the burden of diabetic macular edema (DME). By identifying DR in its early stages, timely interventions can prevent its progression to DME, one of the leading causes of #vision loss. Through #collaboration among healthcare providers, policymakers, NGOs, and industry, we can pool resources to enable widespread screening, raise awareness, and expand #access to care. These joint efforts not only reduce preventable blindness but also mitigate the societal and #economic challenges linked to vision impairment, enhancing patients' quality of life and boosting #productivity. Partnerships at Roche are not only integrated into our global business strategy – they are its driving force. Looking ahead, we aspire to create a sustainable future where all Indonesians at risk of DR and DME have the opportunity for timely diagnosis, effective treatment, and improved outcomes. #RocheOphtalmology #Impact

Peritoneal Dialysis in East Asia. Japan leads for care, and technological advancement to support Automated PD with USB-enabled blood glucose device, blood pressure monitor, BMI monitor. Government support helps technological innovation - specific to Automated PD patients, a subsidised remote monitoring fee is paid out monthly to patients. Taiwan and South Korea share similar PD share (and falling): older patient demographics likely cause while specific to Taiwan, expectations gap negated the PD-preferred policy. China is likely to see massive take up of PD; it has a PD-preferred policy, PD cost effectiveness, and its vastness. #CAPD #CKD #RRT #dialysis

Advancing the Future of Elderly Care through Integrated Approaches! Delving into the critical issue of irrational drug combinations, the latest article, "Overuse of Montelukast in Irrational Drug Combinations in India: Need for Regulation," by Lancelot Pinto, and Sanjitha Muneeswaran, offers a fresh perspective on improving preventive medicine in India.  This research is a must-read for those committed to reshaping healthcare for older adults.  📖 Explore the full article in the September-October 2024 issue of here: https://lnkd.in/du5ZqHzS ✍️ Submit your article via our online portal:  https://lnkd.in/dhn8teVj #PreventiveMedicine #ElderlyCare #HealthcareInnovation #PublicHealth #PMRR

HiRO ANZ achieved rapid site activation and met the initial recruitment target of 450 participants within the 5-month period for a Phase 2 obesity clinical trial. Our collaboration with sites to initiate pre-screening and strategic planning allowed us to adapt quickly, even as the target increased to 495 participants over 7 months. Learn more about our recruitment strategies here: https://lnkd.in/gJZtUBP4 #ClinicalTrials #PatientRecruitment #HiROANZ #HealthcareInnovation

#Medical_Ventilator Market Foresees a Substantial Revenue Surge from 2023 to 2032 https://lnkd.in/gWXQYt_M The market is primarily driven by rising #population, #urbanization, and #chronic #respiratory #diseases such #asthma. Furthermore, modern lifestyle factors such as #smoking are major contributors to the #demand for ventilators. High prevalence of chronic respiratory diseases primarily contribute towards the #growth of the #mechanical #ventilator market. Hamilton Medical Getinge Philips Medtronic ResMed Vyaire Medical GE HealthCare Weinmann Mindray Löwenstein Medical heyer medical AG Aeonmed East Africa eVent Medical, Ltd #Medical_Ventilator #medical_device #business_opportunities #marketanalysis #marketresearch #opportunities #business #future 

Fantastic Day 1 at the BHBIA conference - highlights below... 1. An insightful talk on how the 'Hero's journey' can be a replacement for our typical patient journey milestones - highlighting the importance of putting the patient viewpoint front and centre. #ElmaResearch 2. Lumanity's very own Thomas Markham presenting an inspiring piece on the TikTok revolution and how pharma can utilise short form content to boost insights! #Lumanity 3. An interesting collab between #Pfizer and #Creation on how to get the best out of DOLs and engaging them long term. 4. Great workshop run on how the 9 day fortnight can work (Do I really need to be at this meeting?! Does this meeting need to be 30 mins?) 5. Amazing session on how to revitalise trackers and arrive at the important KPIs for a brand. #BoxeeGroup 6. Case study on Nurses and obesity, showing the need to consider social prescribing along with traditional pharmaological intervations. Araceli Camargo Looking forward to an AI focussed Day 2 tomorrow! #BHBIA2024 #BHBIA #socialmedialistening #healthcareinsights #healthcare #businessinsights #pharma

📣 [WEEK 1 AUGUST MEDICAL NEWS HIGHLIGHTS] 📣  Kick off August with the latest medical information from MIMS. To provide the most reliable and trustworthy information, MIMS cordially invites healthcare professionals to join us in updating the latest medical news through the video.  For the complete article, please click the link below or visit mims.com: 1. Disrupted circadian rhythm a modifiable risk factor for Alzheimer’s disease?: https://lnkd.in/gsHx3Dhp  2. More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis: https://lnkd.in/gSXePDnN  3. TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC: https://lnkd.in/gKWxmwCK  4. Prior MI or stroke may predict diuretic use for HTN management: https://lnkd.in/gXCiPVb4  5. Tofacitinib for JIA safe, effective up to 4 years: https://lnkd.in/gvqeBUGm   -------------  MIMS Vietnam - Empowering healthcare communities to improve patient outcomes  #MIMS #MIMSVietnam #medicalnews

Asia Pacific #Lancet and #Pen_Needles_Market are flourishing because of the rising prevalence of chronic diseases and rapidly aging population in countries across the region. 🌐𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐭𝐨 𝐁𝐥𝐮𝐞𝐖𝐞𝐚𝐯𝐞 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 "𝐀𝐬𝐢𝐚 𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐋𝐚𝐧𝐜𝐞𝐭 𝐚𝐧𝐝 𝐏𝐞𝐧 𝐍𝐞𝐞𝐝𝐥𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭"➖https://lnkd.in/geUDFzxJ ▶ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: ✔BD,  ✔Novo Nordisk  ✔B. Braun Group  ✔SARA HEALTHCARE LIMITED,  ✔Jiangsu Huida Medical Instruments Co., Ltd,  ✔Nanchang Yili Medical Instrument Co., Ltd, ✔Cardinal Health, ✔Phoenix Healthcare LLC and ✔Terumo Medical Corporation 📢𝐌𝐚𝐫𝐤𝐞𝐭 – 𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫: Asia Pacific Lancet and #Pen_Needles Market is segmented into #clinics, #hospitals, #medical_institutions, and others. The hospital segment accounts for the highest #market_share. The market's #growth is mainly attributed to the high number of out-patient visits to hospitals for their regular #blood_sugar level checks and insulin shots. #blueweave #Consulting #marketresearch #marketforecast #healthcare